<!DOCTYPE html>
<html lang="en">
  <head>
    <title>NezNet.Site</title>

    <link rel="icon" type="image/png" href="../../images/universal/logo.png" />

    <meta name="viewport" content="width=device-width, initial-scale=1">
    <meta charset="utf-8">

    <script src="/NezNet.Site/libraries/include-html.js"></script>

    <!-- Imports stylesheet -->
    <link rel="stylesheet" href="../../style.css">
  </head>

  <body>
    <!-- Please don't remove the next 2 lines! -->
    <div id="top"></div>
    <div id="skip"><a href="#content">Skip to content</a></div>

    <div id="container">
      <div id="sidebar">
        <div id="sidebar-content">
          <!-- Profile picture image -->
          <div class="icon"><img src="../../images/universal/pfp.png" alt="Profile picture" /></div>
          <div include-html="../../main-menu/site-name.html"></div>

          <!-- Navigation menu  -->
          <nav id="main-menu">
            <ul>
              <div include-html="../../main-menu/links.html"></div>
            </ul>
          </nav>
          <div include-html="../../main-menu/site-message.html"></div>
        </div>
      </div>

      <!-- Content area -->
      <main id="content">
        <!-- Section tags must be used for blocks -->
        <section class="full">
          <h1><b>Masculinizing GAHT Information</b></h1>
          <p>Masculinizing hormone therapy (also known as testosterone-based GAHT) is typically undertaken by transmasculine or non-binary people aiming to   appear and feel more masculine, it typically involves the administration of a form of testosterone either though injection, patches or gels <A href="#1">[1]</A>.</p>
        </section>

        <section class="full">
          <h1><b>Effects</b></h1>
          <p>Keep in mind that effect strength and onset can vary greatly between individuals, consider this table as an approximate guide only.</p>
          <table>
            <tr>
              <th>Effect</th>
              <th>Expected Onset</th>
              <th>Expected Maximum Onset</th>
            </tr>
            <tr>
              <td>Skin oiliness/acne</td>
              <td>1–6 months</td>
              <td>1–2 years</td>
            </tr>
            <tr>
              <td>Facial/body hair growth</td>
              <td>6-12 months</td>
              <td>>5 years</td>
            </tr>
            <tr>
              <td>Scalp hair loss</td>
              <td>6-12 months*</td>
              <td>>5 years</td>
            </tr>
            <tr>
              <td>Increased muscle mass/strength</td>
              <td>6–12 months</td>
              <td>2–5 years**</td>
            </tr>
            <tr>
              <td>Fat redistribution</td>
              <td>1–6 months</td>
              <td>2–5 years</td>
            </tr>
            <tr>
              <td>Cessation of periods</td>
              <td>1–6 months</td>
              <td>1-2 years</td>
            </tr>
            <tr>
              <td>Clitoral enlargement</td>
              <td>1–6 months</td>
              <td>1–2 years</td>
            </tr>
            <tr>
              <td>Vaginal atrophy</td>
              <td>1–6 months</td>
              <td>1–2 years</td>
            </tr>
            <tr>
              <td>Deepened voice</td>
              <td>1-6 months</td>
              <td>1–2 years</td>
            </tr>
            <tr>
              <td>Increased sexual desire <A href="#1">[1]</A></td>
              <td>Variable</td>
              <td>Variable</td>
            </tr>
            <tr>
              <td colspan="3">*Very dependent on age and genetics, effect may be small <A href="#2">[2]</A>.</td>
            </tr>
            <tr>
              <td colspan="3">**Significantly dependent on amount of exercise <A href="#2">[2]</A>.</td>
            </tr>
          </table>
          <p>Table adapted from Standards of Care for the Health of Transgender and Gender Diverse People, Version 8 <A href="#3">[3]</A>.</p>
          <p>Learn more about the effects of testosterone-based GAHT <a href="effects.html">here</a>.</p>
        </section>

        <section class="full">
          <h1><b>Side Effects/Risks</b></h1>
          <table>
            <tr>
              <th>Risk Level</th>
              <th>Side Effect</th>
            </tr>
            <tr>
              <td>Likely increased risk</td>
              <td>Polycythemia*</td>
            </tr>
            <tr>
              <td></td>
              <td>Infertility*</td>
            </tr>
            <tr>
              <td></td>
              <td>Acne</td>
            </tr>
            <tr>
              <td></td>
              <td>Pattern hair loss</td>
            </tr>
            <tr>
              <td></td>
              <td>Hypertension</td>
            </tr>
            <tr>
              <td></td>
              <td>Sleep apnea</td>
            </tr>
            <tr>
              <td></td>
              <td>Weight gain</td>
            </tr>
            <tr>
              <td></td>
              <td>Decreased HDL cholesterol</td>
            </tr>
            <tr>
              <td></td>
              <td>Increased LDL cholesterol</td>
            </tr>
            <tr>
              <td>likely increased risk with presence of additional risk factors</td>
              <td>Cardiovascular disease</td>
            </tr>
            <tr>
              <td></td>
              <td>Hypertriglyceridemia</td>
            </tr>
            <tr>
              <td>Possible increased risk with presence of additional risk factors</td>
              <td>Type 2 diabetes</td>
            </tr>
            <tr>
              <td></td>
              <td>Cardiovascular disease</td>
            </tr>
            <tr>
              <td>No increased risk or inconclusive</td>
              <td>Low Bone Mass/osteoporosis</td>
            </tr>
            <tr>
              <td></td>
              <td>Breast, cervical, ovarian, uterine cancer</td>
            </tr>
            <tr>
              <td colspan="2">*Shown to be clinically significant.</td>
            </tr>
          </table>
          <p>Table adapted from Standards of Care for the Health of Transgender and Gender Diverse People, Version 8 <A href="#3">[3]</A>.</p>
        </section>

        <section class="full">
          <h1><b>Hormone Regimes</b></h1>
          <p>Always consult a medical professional before starting GAHT.</p>
          <p>The following table is based of New Zealand and international standards and is only meant to inform the audience of what to expect before a medical consultation about GAHT. Dosages and prescriptions should always be discussed with a medical professional, as the information presented here is only a broad overview and the full depth of facts and information about certain medicines may not be present here.</p>
          <table>
            <tr>
              <th>Testosterone Formulation</th>
              <th>Standard Starting Dose </th>
              <th>Maximum (Usual Maintenance) Dose</th>
              <th>Notes</th>
            </tr>
            <tr>
              <td>Testosterone cypionate</td>
              <td>100mg intramuscular/subcutaneous injection every 2 weeks or 50mg subcutaneous injection weekly</td>
              <td>200mg intramuscular/subcutaneous injection every 2 weeks or 100mg subcutaneous injection weekly</td>
              <td>Testosterone level should be measured by a health professional mid-way between injections. Patients can be taught to self-inject by their doctor.</td>
            </tr>
            <tr>
              <td>Testosterone esters</td>
              <td>125mg intramuscular injection every 3 weeks</td>
              <td>250mg intramuscular injection every 3 weeks</td>
              <td>Testosterone level should be measured by a health professional mid-way between injections. Patients can be taught to self-inject by their doctor.</td>
            </tr>
            <tr>
              <td>Testosterone undecanoate</td>
              <td>Less commonly used as a starting testosterone, but can be started at 500mg intramuscular injection. The second dose can be given after 6 weeks to achieve steady state and thereafter continue 12-weekly</td>
              <td>750–1000mg intramuscular injection every 10–14 weeks</td>
              <td>Testosterone level should be checked by a health professional immediately prior to injection. Injection must be given by a health professional (due to risk of oil embolism).</td>
            </tr>
            <tr>
              <td>Testosterone transdermal patches</td>
              <td>5mg daily</td>
              <td>5–10mg daily</td>
              <td>Testosterone level should be measured in the morning by a health professional. Skin irritation is common.</td>
            </tr>
            <tr>
              <td>Testosterone gel</td>
              <td></td>
              <td>50-100mg daily</td>
              <td>Starting dosage and testosterone monitoring interval not indicated on the information source <A href="#3">[3]</A>.</td>
            </tr>
          </table>
          <p>Table adapted from Guidelines for gender affirming healthcare for gender diverse and transgender children, young people and adults in Aotearoa New Zealand <A href="#4">[4]</A>.</p>
        </section>

        <section class="full">
          <h1><b>Citations</b></h1>
          <ul>
            <A name="1"><li>[1]</A> Radix A. 2019. Hormone Therapy for Transgender Adults. Urologic Clinics of North America. 46(4):467–473. doi:<a href="https://doi.org/10.1016/j.ucl.2019.07.001">https://doi.org/10.1016/j.ucl.2019.07.001</a>.</li>
            <A name="2"><li>[2]</A> Coleman E, Bockting W, Botzer M, Cohen-Kettenis P, DeCuypere G, Feldman J, Fraser L, Green J, Knudson G, Meyer WJ, et al. 2012. Standards of Care for the Health of Transsexual, Transgender, and Gender-Nonconforming People, Version 7. International Journal of Transgenderism. 13(4):165–232. doi:<a href="https://doi.org/10.1080/15532739.2011.700873">https://doi.org/10.1080/15532739.2011.700873</a>. <a href="https://www.tandfonline.com/doi/abs/10.1080/15532739.2011.700873">https://www.tandfonline.com/doi/abs/10.1080/15532739.2011.700873</a>.</li>
            <A name="3"><li>[3]</A> Coleman E, Radix AE, Bouman WP, Brown GR, de Vries ALC, Deutsch MB, Ettner R, Fraser L, Goodman M, Green J, et al. 2022. Standards of Care for the Health of Transgender and Gender Diverse People, Version 8. International Journal of Transgender Health. 23(S1):S1–S259. doi:<a href="https://doi.org/10.1080/26895269.2022.2100644">https://doi.org/10.1080/26895269.2022.2100644</a>. <a href="https://www.tandfonline.com/doi/full/10.1080/26895269.2022.2100644">https://www.tandfonline.com/doi/full/10.1080/26895269.2022.2100644</a>.</li>
            <A name="4"><li>[4]</A> Oliphant J, Veale J, Macdonald J, Carroll R, Johnson R, Harte M, Stephenson C, Bullock J. 2018. Guidelines for gender affirming healthcare for gender diverse and transgender children, young people and adults in Aotearoa New Zealand. researchcommonswaikatoacnz. <a href="https://hdl.handle.net/10289/12160">https://hdl.handle.net/10289/12160</a>.</li>
          </ul>
        </section>

        <footer id="main-footer">
          <p>Updated 12/8/2024</p>
          <div include-html="../../footer/links.html"></div>
        </footer>
      </main>
    </div>

    <script>
      includeHTML();
    </script>
  </body>
</html>
